2-(2,3-dicarboxycyclopropyl)glycine has been researched along with mgs 0028 in 1 studies
Studies (2-(2,3-dicarboxycyclopropyl)glycine) | Trials (2-(2,3-dicarboxycyclopropyl)glycine) | Recent Studies (post-2010) (2-(2,3-dicarboxycyclopropyl)glycine) | Studies (mgs 0028) | Trials (mgs 0028) | Recent Studies (post-2010) (mgs 0028) |
---|---|---|---|---|---|
14 | 0 | 1 | 10 | 0 | 4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Blanco-Urgoiti, J; Collado, I; Espinosa, JF; Johnson, BG; Kingston, AE; Mazón, A; Pedregal, C; Schoepp, DD; Wright, RA | 1 |
1 other study(ies) available for 2-(2,3-dicarboxycyclopropyl)glycine and mgs 0028
Article | Year |
---|---|
(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.
Topics: Animals; Anti-Anxiety Agents; Bridged Bicyclo Compounds; Cell Line; Cyclopropanes; Glycine; Ligands; Models, Molecular; Rats; Receptors, Metabotropic Glutamate; Reflex, Startle; Stereoisomerism | 2002 |